Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.740
+0.120 (3.31%)
At close: Aug 13, 2025, 4:00 PM
3.730
-0.010 (-0.27%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.11% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.11%
P/S Ratio
15,167.00
Revenue / Employee
$339
Employees
59
Market Cap
303.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALT News
- 5 hours ago - Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 hours ago - These Analysts Slash Their Forecasts On Altimmune Following Q2 Results - Benzinga
- 1 day ago - Altimmune Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 2 days ago - Altimmune Board of Directors Appoints Jerry Durso as Chairman - GlobeNewsWire
- 8 days ago - Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - GlobeNewsWire
- 25 days ago - ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 5 weeks ago - Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - GlobeNewsWire
- 6 weeks ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga